Penumbra’s Newly Expanded swiftPAC^™ Coil Line Poised to Help Physicians Meet Growing Demand for Neurosurgical Conditions

Penumbra’s swiftPAC coils are designed as a soft space-seeking “liquid metal” that conforms to the target vessel for dense packing. These attributes are designed to provide versatility across a variety of clinical applications, including middle meningeal artery (MMA) embolization, carotid cavernous fistula (CCF) embolization, and coiling small aneurysms. Penumbra recently expanded the product offering to include 20 cm and 25 cm coils.

With a unique coil shape, swiftPAC is engineered for efficient, dense packing. Its innovative 2D sinusoidal shape is designed to help the coil break effortlessly to seek empty space. With a softness value of .093, swiftPAC is one of the softest 10-system coils on the market. It is now available in an expanded range of lengths — including the newly added 20 cm and 25 cm options — to optimize embolization across vessel sizes and anatomy.

Additionally, swiftPAC coils are designed to offer physicians the ability to deploy and reposition with precision before detaching. This enables physicians to manage therapeutic embolization — particularly in the MMA — while minimizing the procedural risks associated with liquid embolics and their potential for unintended anastomotic passage.^1,2

Meeting the Growing Demand for MMA Embolization

Chronic subdural hematoma is the most common neurosurgical condition in seniors, and its incidence is rising as that population grows.³ Researchers estimate that by the end of the decade, it will become the most common craniosurgical disease.⁴

In recent years, MMA embolization has shown promise in minimizing recurrence of chronic subdural hematoma. MMA embolization could transform non-acute subdural hematoma management, especially in the elderly.⁵ Researchers estimate that MMA embolization procedures for chronic subdural hematomas will exceed 140,000 cases per year in seniors and outnumber endovascular therapy for large vessel strokes.¹

swiftPAC is designed to help physicians address the growing demand of MMA embolization harnessing the power of a technology that is engineered to occlude like a liquid with the comparative efficiencies of a coil embolization system.

“swiftPAC advances embolization by offering both occlusion efficiency and precision, two essential factors in meeting the growing demand for neurovascular procedures extending beyond MMA embolization,” says Dr. Adi Iyer, M.D., of Providence Saint Joseph Medical Center.

swiftPAC has a .0135” primary diameter deliverable through .0165” microcatheters and is available in a range of lengths from 3 cm to 60 cm, including the recently introduced 20 cm and 25 cm, to optimize a physician’s embolic options.

Want to learn more about swiftPAC? Request a demo.

Important Safety Information
Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/products/neuro-embolization-system/. Caution: Federal (USA) law restrictions these devices to sale by or on the order of a physician. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found at peninc.info/risk.

Copyright ©2025 Penumbra, Inc. All rights reserved. swiftPAC is a registered trademark or trademark of Penumbra, Inc. in the USA and other countries. All other trademarks are the property of their respective owners.

<sup>1. Khattar NK, Sims JJ, Hoffman H, Nickele C, Inoa V, Hoit DA, Strickland AE, Goyal N. Safety and immediate outcomes of the new generation Swift PAC coil in cerebrovascular pathology: A case series. Interv Neuroradiol. 2025 May 21:15910199251343735. doi: 10.1177/15910199251343735.
2. Chu T, Sindewald R, Stone LE, Wali AR, Santiago-Dieppa D. Middle meningeal artery embolization: A scoping review of trends and outcomes by embolization material. Surgical Neurology International. 2025 March 14;16:88. Doi: 10.25259/SNI_1003_2024.
3. Rai AT, Halak AA, Lakhani DA, et al. Population-based estimates suggest middle meningeal artery embolization for subdural hemato mas could significantly expand the scope of neurovascular therapies. J Neurointerv Surg. 2024 Apr 11:jnis-2024-021686. doi:10.1136/jnis-2024-021686
4. Chen H, Colasurdo M, Malhotra A, et al. Advances in chronic subdural hematoma and membrane imaging. Front Neurol. 2024 Apr 25;15:1366238. doi:10.3389/fneur.2024.1366238
5. Fiehler J, Bechstein M. Does every subdural hematoma patient need an embolization? Clin Neuroradiol. 2024;34(2):289-291. doi:10.1007/s00062-024-01425-z</sup>